On Nov 08, major Wall Street analysts update their ratings for $Tandem Diabetes Care (TNDM.US)$, with price targets ranging from $40 to $75.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $58 to $60.
UBS analyst Danielle Antalffy maintains with a hold rating, and maintains the target price at $40.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $45.
Stifel analyst Mathew Blackman maintains with a buy rating, and maintains the target price at $60.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and maintains the target price at $65.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
Tandem Diabetes delivered another solid growth quarter, with an increase in full-year growth guidance to 17%-18%. This performance is largely driven by the continued success of the Mobi launch.
Although Tandem Diabetes has reported its third consecutive quarter of surpassing expectations and raising forecasts, the company's stock performance did not reflect these positive results, which may be due to uncertainties about future growth prospects. It is suggested that the company has completely navigated through its previous challenges and that the fundamental aspects of the business are expected to progressively enhance going forward. Nevertheless, a more cautious stance is being maintained until there is greater assurance in the enduring factors that will drive sales growth.
Concerns regarding Tandem Diabetes' third-quarter revenue outperformance were noted, with contributing factors including timing benefits from U.S. supplies and orders from international distributors. United States pump shipments for the quarter were reported to align closely with expectations.
Here are the latest investment ratings and price targets for $Tandem Diabetes Care (TNDM.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.